CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 66 enrolled
Drug / intervention
Escitalopram 20 mg +1 moredrug
Likely dose
Escitalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04239339
NCT04239339Phase 4Completed
CompareCT.gov

Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers

Rigshospitalet, Denmark·interventional·Posted Jan 27, 2020·Updated Nov 18, 2023

In Brief

A Phase 4 clinical trial evaluating Escitalopram 20 mg and Placebo for Healthy. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The aim of this project is: * To apply a pharmacological tool of selective serotonin (5-hydroxytryptamine, 5-HT system) reuptake inhibition in healthy humans. Specifically: * To investigate how sub-chronic administration of 20 mg of escitalopram affects cognitive performance ('cold' cognition) and social-emotional functioning ('hot' cognition) compared with placebo; and * To investigate how sub-chronic administration of 20 mg of escitalopram affects functional brain activation during a paradigm of reinforcement learning following drug administration compared with placebo, and how activation relates to cognitive performance and social-emotional functioning.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesDenmark
CollaboratorsUniversity of Cambridge, Lundbeck Foundation

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJan 27, 2020
Enrollment StartApr 28, 2020
Primary CompletionOct 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.4 years ago

Interventions

Escitalopram 20 mgdrug

20mg daily for approximately 3 weeks.

Placebodrug

Placebo daily for approximately 3 weeks.